Ziprasidone-associated depressive state in schizophrenic patients

Clinical Neuropharmacology

Volumn 30, Issue 6, 2007, Pages 357-361

  Kaptsan, Alexander ^a   Dwolatzky, Tzvi ^a   Lerner, Vladimir ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b MENTAL HEALTH CENTER   (Israel)

Author keywords

Atypical antipsychotics; Schizophrenia; Ziprasidone associated depression

Indexed keywords

CITALOPRAM; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTRALINE; VALPROIC ACID; ZIPRASIDONE;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HUMAN; MALE; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SUICIDAL IDEATION; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; SCHIZOPHRENIA; THIAZOLES;

EID: 37349018280     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/wnf.0b013e31805751a3     Document Type: Article

References (25)

1. Bartels SJ, Drake RE. Depressive symptoms in schizophrenia: comprehensive differential diagnosis. Compr Psychiatry 1988;29:467-483.
2. Gangat AE, Simpson MA, Naidoo LR. Medication as a potential cause of depression. S Afr Med J 1986;70:224-226.
3. Ganzini L, Walsh JR, Millar SB. Drug-induced depression in the aged. What can be done? Drugs Aging 1993;3:147-158.
4. Griffiths RR, Mumford GK. Caffeine - a drug of abuse? In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press; 1995:1699-1713.
5. Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 1998;155:1490-1501.
6. Bernstein JG. Handbook of Drug Therapy in Psychiatry, 3rd ed. St Louis: Mosby-Year Book, Inc; 1995.
7. Bloch M, Stager S, Braun A, et al. Pimozide-induced depression in men who stutter. J Clin Psychiatry 1997;58:433-436.
8. Gervin M, Browne S, Garavan J, et al. Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology. Eur Psychiatry 1999;14:405-409.
9. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993;19:609-618.
10. Moller HJ, von Zerssen D. Depressive states occurring during the neuroleptic treatment of schizophrenia. Schizophr Bull 1982;8:109-117.
11. Kaplan HI, Sadock BJ, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 7th ed. Baltimore: Lippincott Williams & Wilkins; 1999.
12. Masan PS. Atypical antipsychotics in the treatment of affective symptoms: a review. Ann Clin Psychiatry 2004;16:3-13.
13. Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004;65:217-221.
14. Margolese HC, Annable L, Dion Y. Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. J Clin Psychiatry 2002;63:1040-1044.
15. Mergui J, Jaworowski S, Lerner V. Quetiapine-associated depression in a patient with schizophrenia. Clin Neuropharmacol 2005;28:133-135.
16. Bandelow B, Muller P, Frick U, et al. Depressive syndromes in schizophrenic patients under neuroleptic therapy. ANI Study Group Berlin, Dusseldorf, Gottingen, Munich, Federal Republic of Germany. Eur Arch Psychiatry Clin Neurosci 1992;241:291-295.
17. Harrow M, Yonan CA, Sands JR, et al. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophr Bull 1994;20:327-338.
18. Barnes TR, McPhillips MA. How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia. Int Clin Psychopharmacol 1995;10(suppl 3):115-121.
19. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995;275:101-113.
20. 1A receptor activation. Neuropsychopharmacology 1999;21:622-631.
21. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68:29-39.
22. 2C receptors. J Pharmacol Exp Ther 2000;295:226-232.
23. Rollema H, Lu Y, Schmidt AW, et al. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 2000;48:229-237.
24. Krakowski M, Czobor P, Volavka J. Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes. Psychiatry Res 1997;71:19-26.
25. Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991;148:1474-1486.